>>> Valeant Pharma beats by $0.12, reports revs in-line; raises Q4, FY15 cash EP

Valeant Pharma beats by $0.12, reports revs in-line; raises Q4, FY15 cash EPS guidance

Reports Q3 (Sep) earnings of $2.11 per share, excluding non-recurring items, $0.12 better than the Capital IQ Consensus Estimate of $1.99; revenues rose 33.4% year/year to $2.06 bln vs the $2.06 bln consensus.

Co guided up on Sept 24.
Total same store sales organic growth was 19%, including impact from generics Bausch + Lomb organic growth was 12%, adjusted only for foreign exchange.

Co issues upside guidance for Q4, sees EPS of $2.45-2.55, excluding non-recurring items, vs. $2.38 Capital IQ Consensus.

Expect double-digit same store organic growth in the fourth quarter

Co issues upside guidance for FY15, raises EPS to $10.00, excluding non-recurring items, from $9.65 vs. $9.58 Capital IQ Consensus; raises 2015 outlook to +10% organic growth.